Bluejay Therapeutics makes progress in Hepatitis B and D Trials

Bluejay Therapeutics has reported the successful completion of a Phase Ia trial and enrolment of the initial Phase Ib cohorts for BJT-778, a monoclonal antibody targeting hepatitis B surface antigen.